Newsletters

How will #biopharma tackle #COVID19 in 2021? @jbuell01, President and COO of $AGEN, and other leading industry experts answer @PharmaScrip's thought-provoking question. Read their responses here: bit.ly/39HJNJM

Agenus to Participate in B. Riley Securities' Oncology Investor Conference investor.agenusbio.com/news-releases/…

#AI-driven #biomarker detection is critical for optimization of #IO cancer treatments. #VISION is designed to accurately predict treatment responses, important for identifying optimal therapies & combinations. Learn more from Dr. Cailin Joyce: bioprocessintl.com/analytical/dia…

2021- Agenus Focusing on Our Highest Potential Opportunities – READ MORE on our focus on our highest potential I-O product candidates, as well as significant partnership opportunities: agenusbio.com/newsletters/v4…

The #biotech industry and the way we do business have been transformed by #COVID19. Listen to @jbuell01 speak with @DatasiteGlobal about $AGEN's innovative strategies for relationship building and #dealmaking in a digital setting #JPM2021 twitter.com/DatasiteGlobal…

Stay tuned for the first issue of our 2021 series on January 12, which will outline our plans for the new year!

$AGEN latest newsletter now available: A Pivotal Year: 2020 in Review 2020 has been a year of innovation & progress for Agenus. The conclusion of our 2020 newsletter series discusses Agenus' achievements this year: agenusbio.com/newsletters/v3…

Save the date! @Agentus_CellTX twitter.com/Agentus_CellTX…

Bali #BLA filing: 2 late responses w bali mono require 6 mo follow-up. Bali mono and bali/zali combo on track to be filed. Listen to full discussion here: investor.agenusbio.com/events/event-d… rb.gy/cci6ua (2/2)

$AGEN President & COO @jbuell01 spoke w Umer Raffat at the Evercore ISI 3rd Annual #HealthCONx Conference last wk about Agenus' strong pipeline based on #immunology. Key points covered: AGEN1181 responses in MSS disease, PD-L1(-) tumors, & a genetic polymorphism. (1/2)

$AGEN is excited to welcome Dr. @JoeGrossman7 as VP Head of Exploratory Medicine! Dr. Grossman is a GI cancer expert who joins Agenus from @harvardmed and @BIDMChealth. Read more about Dr. Grossman and his thoughts on AGEN1181 Ph2 trial expansion: investor.agenusbio.com/news-releases/…

AGEN1181, Fc-enhanced anti-CTLA-4, reports new responses in CRC; expanded Phase 2 trial underway. Responses in tumors unlikely to respond to CPIs (PD-L1(-), MSS endometrial, CRC, ovarian). investor.agenusbio.com/news-releases/…

Completion of Balstilimab BLA Filing Extended To 1H2021 investor.agenusbio.com/news-releases/…

AgenT-797 @Agentus_CellTX iNKT #celltherapy promotes direct tumor killing & tumor microenvironment conditioning & can be manufactured efficiently at a low cost. #COVID19 trial is underway @WeillCornell and cancer trials are expected to begin soon #SITC2020 agenusbio.com/wp-content/upl…

$AGEN latest newsletter now available: Leveraging the Immune System to Defeat COVID-19 #CellTherapy shows promise as treatment for #COVID19. iNKT cell therapy has entered the clinic to treat patients w moderate to severe cases of COVID-19 @Agentus_CellTX agenusbio.com/wp-content/upl…

AGEN1181, our Fc-enhanced next-gen #CTLA4, was presented at #SITC2020 by Dr. @ODayMD who will join $AGEN as CMO. AGEN1181 shows durable clinical benefit & no neuroendocrine toxicities; first known CTLA-4 to show selective depletion of intratumoral Tregs agenusbio.com/wp-content/upl…

$AGEN Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab investor.agenusbio.com/news-releases/…

$AGEN to Participate in Evercore ISI 3rd Annual #HealthCONx Conference investor.agenusbio.com/news-releases/…

$AGEN's #CTLA4 zali is active in #PD1 failures as shown in a study in #raretumors presented at #SITC2020. Out of 28 evaluable patients: DCR of 51.9%; 1 CR, 2 PRs. We have launched a Ph2 trial of bali + zali w SOC in #softtissuesarcoma w @breelynwilkyMD agenusbio.com/wp-content/upl…